• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment.乳腺中的表观遗传改变:对乳腺癌检测、预后及治疗的意义。
Semin Cancer Biol. 2009 Jun;19(3):165-71. doi: 10.1016/j.semcancer.2009.02.007. Epub 2009 Feb 20.
2
Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer.HOPX的表观遗传沉默促进乳腺癌的侵袭性。
Cancer Lett. 2017 Jan 1;384:70-78. doi: 10.1016/j.canlet.2016.10.017. Epub 2016 Oct 15.
3
Aberrant promoter CpG methylation and its translational applications in breast cancer.异常启动子CpG甲基化及其在乳腺癌中的转化应用。
Chin J Cancer. 2013 Jan;32(1):12-20. doi: 10.5732/cjc.011.10344. Epub 2011 Nov 4.
4
Epigenetic mechanisms of breast cancer: an update of the current knowledge.乳腺癌的表观遗传学机制:最新知识综述。
Epigenomics. 2014;6(6):651-64. doi: 10.2217/epi.14.59.
5
Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.肿瘤中 DNA 修复基因启动子超甲基化和浸润性导管乳腺癌患者血清 DNA 的临床意义。
Life Sci. 2010 Jul 17;87(3-4):83-91. doi: 10.1016/j.lfs.2010.05.001. Epub 2010 May 12.
6
UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer.UHRF1 与散发性乳腺癌中 BRCA1 的表观遗传沉默有关。
Breast Cancer Res Treat. 2010 Sep;123(2):359-73. doi: 10.1007/s10549-009-0652-2. Epub 2009 Nov 27.
7
Diagnostic utility of epigenetics in breast cancer - A review.表观遗传学在乳腺癌中的诊断效用——综述
Cancer Treat Res Commun. 2019;19:100125. doi: 10.1016/j.ctarc.2019.100125. Epub 2019 Feb 19.
8
BRCA1 Promoter Methylation and Clinicopathological Characteristics in Sporadic Breast Cancer Patients in Indonesia.印度尼西亚散发性乳腺癌患者中BRCA1启动子甲基化与临床病理特征
Asian Pac J Cancer Prev. 2018 Sep 26;19(9):2643-2649. doi: 10.22034/APJCP.2018.19.9.2643.
9
Epigenetic modulation of BRCA-1 and MGMT genes, and histones H4 and H3 are associated with breast tumors.BRCA-1 和 MGMT 基因以及组蛋白 H4 和 H3 的表观遗传调节与乳腺癌有关。
J Cell Biochem. 2019 Aug;120(8):13726-13736. doi: 10.1002/jcb.28645. Epub 2019 Apr 2.
10
DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.癌症患者的DNA甲基化和组蛋白修饰:潜在的预后和治疗靶点。
Methods Mol Biol. 2007;361:25-62. doi: 10.1385/1-59745-208-4:25.

引用本文的文献

1
Targeting Triple-Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements.靶向三阴性乳腺癌:耐药机制与治疗进展
Cancer Med. 2025 May;14(9):e70803. doi: 10.1002/cam4.70803.
2
Mechanism of action of genistein on breast cancer and differential effects of different age stages.染料木黄酮对乳腺癌的作用机制及不同年龄阶段的差异效应。
Pharm Biol. 2025 Dec;63(1):141-155. doi: 10.1080/13880209.2025.2469607. Epub 2025 Feb 25.
3
Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.SIRT1抑制剂西利西他增强了紫杉醇在腔面型和三阴性乳腺癌中的活性:计算机模拟、体外和体内研究。
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2458554. doi: 10.1080/14756366.2025.2458554. Epub 2025 Feb 12.
4
Methylation of promoter in sporadic breast cancer.散发性乳腺癌中启动子的甲基化
Indian J Med Res. 2023 Jan;158(1):85-87. doi: 10.4103/ijmr.ijmr_1574_22.
5
In silico analysis of differentially expressed-aberrantly methylated genes in breast cancer for prognostic and therapeutic targets.乳腺癌中差异表达的异常甲基化基因用于预后和治疗靶点的计算机分析
Clin Exp Med. 2023 Nov;23(7):3847-3866. doi: 10.1007/s10238-023-01060-x. Epub 2023 Apr 7.
6
Chromatin Remodeling Enzyme Cluster Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Breast Cancer.染色质重塑酶簇预测乳腺癌的预后和治疗策略的临床获益。
Int J Mol Sci. 2023 Mar 15;24(6):5583. doi: 10.3390/ijms24065583.
7
Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner.丙戊酸通过以细胞类型特异性的方式触发不同的反应来抑制 MCF-7 和 MDA-MB231 细胞的细胞生长。
J Transl Med. 2023 Mar 2;21(1):165. doi: 10.1186/s12967-023-04015-8.
8
Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression.地西他滨诱导的人乳腺癌细胞系中DNA甲基化介导的转录组重编程;脱氧胞苷激酶过表达的影响。
Front Pharmacol. 2022 Oct 5;13:991751. doi: 10.3389/fphar.2022.991751. eCollection 2022.
9
Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF-7/SC Breast Cancer Cells.联合十五烷酸和他莫昔芬治疗对 MCF-7/SC 乳腺癌细胞他莫昔芬耐药的影响。
Int J Mol Sci. 2022 Sep 26;23(19):11340. doi: 10.3390/ijms231911340.
10
Gut Metabolites and Breast Cancer: The Continuum of Dysbiosis, Breast Cancer Risk, and Potential Breast Cancer Therapy.肠道代谢物与乳腺癌:肠道菌群失调、乳腺癌风险和潜在乳腺癌治疗的连续性。
Int J Mol Sci. 2022 Aug 22;23(16):9490. doi: 10.3390/ijms23169490.

本文引用的文献

1
Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells.乳腺癌相关成纤维细胞致使上皮细胞中胱抑素M发生AKT1介导的表观遗传沉默。
Cancer Res. 2008 Dec 15;68(24):10257-66. doi: 10.1158/0008-5472.CAN-08-0288.
2
A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology.一种使用高通量测序技术识别RNA聚合酶II结合量变化的泊松混合模型。
BMC Genomics. 2008 Sep 16;9 Suppl 2(Suppl 2):S23. doi: 10.1186/1471-2164-9-S2-S23.
3
Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors.BRCA1的启动子高甲基化与遗传性乳腺癌肿瘤中该基因的无表达相关。
Epigenetics. 2008 May-Jun;3(3):157-63. doi: 10.4161/epi.3.3.6387. Epub 2008 Jun 5.
4
BRCA1 promoter methylation is associated with increased mortality among women with breast cancer.BRCA1基因启动子甲基化与乳腺癌女性患者死亡率增加有关。
Breast Cancer Res Treat. 2009 May;115(2):397-404. doi: 10.1007/s10549-008-0075-5. Epub 2008 Jun 3.
5
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.伴有遗传性和表观遗传性BRCA1缺失的卵巢癌具有独特的分子异常。
BMC Cancer. 2008 Jan 22;8:17. doi: 10.1186/1471-2407-8-17.
6
Triple negative tumours: a critical review.三阴性肿瘤:一项批判性综述。
Histopathology. 2008 Jan;52(1):108-18. doi: 10.1111/j.1365-2559.2007.02889.x.
7
Wwox and Ap2gamma expression levels predict tamoxifen response.Wwox和Ap2γ的表达水平可预测他莫昔芬的反应。
Clin Cancer Res. 2007 Oct 15;13(20):6115-21. doi: 10.1158/1078-0432.CCR-07-1282.
8
Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families.非BRCA1/2肿瘤的免疫组织化学分类确定了不同的组,这些组显示出BRCAX家族的异质性。
Mod Pathol. 2007 Dec;20(12):1298-306. doi: 10.1038/modpathol.3800969. Epub 2007 Sep 21.
9
Correlation between CpG methylation profiles and hormone receptor status in breast cancers.乳腺癌中CpG甲基化谱与激素受体状态之间的相关性
Breast Cancer Res. 2007;9(4):R57. doi: 10.1186/bcr1762.
10
Promoter-associated RNA is required for RNA-directed transcriptional gene silencing in human cells.启动子相关RNA是人类细胞中RNA定向转录基因沉默所必需的。
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12422-7. doi: 10.1073/pnas.0701635104. Epub 2007 Jul 17.

乳腺中的表观遗传改变:对乳腺癌检测、预后及治疗的意义。

Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment.

作者信息

Dworkin Amy M, Huang Tim H-M, Toland Amanda Ewart

机构信息

Integrated Biomedical Science Graduate Program, The Ohio State University, Columbus, OH 43210, USA.

出版信息

Semin Cancer Biol. 2009 Jun;19(3):165-71. doi: 10.1016/j.semcancer.2009.02.007. Epub 2009 Feb 20.

DOI:10.1016/j.semcancer.2009.02.007
PMID:19429480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2734184/
Abstract

Epigenetic alterations of the genome such as DNA promoter methylation and chromatin remodeling play an important role in tumorigenesis. Recent findings indicate epigenetic modifications as key factors in breast carcinogenesis. These modifications are quite appealing as targets for preventative care and therapeutics because of their potential for reversal. Future medical care for breast cancer patients will likely depend upon a better understanding of the roles epigenetic modifications play in carcinogenesis. Here, we discuss the importance of epigenetics in breast cancer detection, prognosis, and therapy with an emphasis on mechanisms and epigenetic contributions to field cancerization effects.

摘要

基因组的表观遗传改变,如DNA启动子甲基化和染色质重塑,在肿瘤发生中起着重要作用。最近的研究结果表明,表观遗传修饰是乳腺癌发生的关键因素。由于这些修饰具有可逆性,作为预防保健和治疗的靶点颇具吸引力。未来乳腺癌患者的医疗护理可能取决于对表观遗传修饰在致癌过程中所起作用的更好理解。在此,我们讨论表观遗传学在乳腺癌检测、预后和治疗中的重要性,重点关注其机制以及对场癌化效应的表观遗传贡献。